Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Crossref DOI link: https://doi.org/10.1007/s10120-016-0670-9
Published Online: 2016-11-17
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nishimura, Takashi
Iwasa, Satoru
Nagashima, Kengo
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
Boku, Narikazu
License valid from 2016-11-17